Country: Ingilterra
Lingwa: Ingliż
Sors: myHealthbox
gliclazide
Mercury Pharmaceuticals Limited
A10BB09
gliclazide
30mg
Modified-release tablet
Oral use
blister packs of 28 or 56
POM - Prescription Only Medicine
APC Pharmaceuticals & Chemicals Ltd
sulphonamides, urea derivative
It is indicated in adults for treatment of non-insulin dependent diabetes (type 2) when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.
Authorised
2014-09-18
1 PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT VAMJU 30 mg modified-release tablets VAMJU 60 mg modified-release tablets Gliclazide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What VAMJU modified-release tablets are and what it is used for 2. What you need to know before you take VAMJU modified-release tablets 3. How to take VAMJU modified-release tablets 4. Possible side effects 5. How to store VAMJU modified-release tablets 6. Contents of the pack and other information 1. WHAT VAMJU MODIFIED-RELEASE TABLETS ARE AND WHAT IT IS USED FOR VAMJU modified release tablets is a medicine that contains the active ingredient gliclazide that reduces blood sugar levels (oral antidiabetic medicine belonging to the sulphonylurea group). VAMJU 30 mg and 60 mg modified-release tablets is used in a certain form of diabetes (type 2 diabetes mellitus) in adults, when diet, exercise and weight loss alone do not have an adequate effect on keeping blood sugar at the correct level. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VAMJU MODIFIED-RELEASE TABLETS DO NOT TAKE VAMJU MODIFIED-RELEASE TABLETS - if you are allergic to gliclazide or any of the other ingredients of thi Aqra d-dokument sħiħ
Vamju 30 mg and 60mg modifiedrelease tablets Summary of Product Characteristics Updated 04Aug2015 | Amdipharm Mercury Company Limited 1. Name of the medicinal product Vamju 30 mg modifiedrelease tablets Vamju 60 mg modifiedrelease tablets 2. Qualitative and quantitative composition Vamju 30 mg: Each modifiedrelease tablet contains 30 mg gliclazide. Vamju 60 mg: Each modifiedrelease tablet contains 60 mg gliclazide. Excipients with known effect: Lactose Vamju 30 mg: Each 30 mg tablet contains 81.9 mg lactose (as monohydrate). Vamju 60 mg: Each 60 mg tablet contains 163.8 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Modifiedrelease tablet. Vamju 30 mg White, biconvex, capsuleshaped tablet, engraved with “GLI 30” on one side and plain on the other side, with dimensions 10.0 x 4.5 mm. Vamju 60 mg White, biconvex, ovalshaped tablet, with a deep breakline on both sides and engraved with “GLI” and “60” on either side of the breakline on both sides, with dimensions 15.0 x 7.0 mm. The 60 mg tablet can be divided into equal doses. 4. Clinical particulars 4.1 Therapeutic indications Vamju is indicated in adults for treatment of noninsulin dependent diabetes (type 2) when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose. 4.2 Posology and method of administration Posology The daily dose may vary from 30 to 120 mg (i.e. 1 to 4 tablets of 30 mg per day or one half to 2 tablets of 60 mg per day) taken orally in a single intake at breakfast time. It is recommended that the tablet(s) be swallowed whole, without crushing or chewing. If a dose is forgotten, there must be no increase in the dose taken the next day. As with any hypogly Aqra d-dokument sħiħ